Dynamic proteome in enigmatic preeclampsia: An account of molecular mechanisms and biomarker discovery

Proteomics - Clinical Applications

Volumn 6, Issue 1-2, 2012, Pages 79-90

  Mary, Sheon ^a   Patil, Gouri V ^a   Kulkarni, Asmita V ^b   Kulkarni, Mahesh J ^a   Joshi, Sadhana R ^b   Mehendale, Savita S ^c   Giri, Ashok P ^a  

^a NATIONAL CHEMICAL LABORATORY   (India)

^b Bharati Vidyapeeth   (India)

^c Bharati Vidyapeeth's Medical College   (India)

Author keywords

Hypertension; Oxidative stress; Pregnancy complication; Proteinuria

Indexed keywords

ANGIOGENIC FACTOR; AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR; PLACENTA PROTEIN; PROTEOME;

BODY FLUID; CELL LINE; DISEASE ASSOCIATION; EPIGENETICS; FUNCTIONAL PROTEOMICS; GENETIC ANALYSIS; HUMAN; HYPOXIA; IMMUNOREACTIVITY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOGENICITY; PLACENTA DISORDER; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION;

AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PROTEOME;

EID: 84858980422     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100089     Document Type: Review

References (141)

1. Khong, T. Y., Liddell, H. S., Robertson, W. B., Defective haemochorial placentation as a cause of miscarriage: a preliminary study. Br. J. Obstet. Gynaecol. 1987, 94, 649-655.
2. Khong, T. Y., De Wolf, F., Robertson, W. B., Brosens, I., Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by smallfor-gestational age infants. Br. J. Obstet. Gynaecol. 1986, 93, 1049-1059.
3. Dommisse, J., Tiltman, A. J., Placental bed biopsies in placental abruption. Br. J. Obstet. Gynaecol. 1992, 99, 651-654.
4. Kim, Y.M., Bujold, E., Chaiworapongsa, T., Gomez, R. et al., Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am. J. Obstet. Gynecol. 2003, 189, 1063-1069.
5. Kim, Y.M., Chaiworapongsa, T., Gomez, R., Bujold, E. et al., Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture ofmembranes. Am. J. Obstet. Gynecol. 2002, 187, 1137-1142.
6. Smith, G. C., Crossley, J. A., Aitken, D. A., Pell, J. P. et al., First-trimester placentation and the risk of antepartum stillbirth. JAMA 2004, 292, 2249-2254.
7. WHO World Health Report, Make Every Mother and Child Count, World Health Organization, Geneva, Switzerland, 2005.
8. Kauma, S., Takacs, P., Scordalakes, C., Walsh, S. et al., Increased endothelial monocyte chemoattractant protein-1 and interleukin-8 in preeclampsia. Obstet. Gynecol. 2002, 100, 706-714.
9. Barton, J. R., Sibai, B. M., Prediction and prevention of recurrent preeclampsia. Obstet. Gynecol. 2008, 112, 359-372.
10. Duckitt, K., Harrington, D., Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005, 330, 565-567.
11. Zhang, J., Patel, G., Partner change and perinatal outcomes: a systematic review. Paediatr. Perinat. Epidemiol. 2007, 21, 46-57.
12. Carr, D. B., Epplein, M., Johnson, C. O., Easterling, T. R. et al., A sister's risk: family history as a predictor of preeclampsia. Am. J. Obstet. Gynecol. 2005, 193, 965-972.
13. Esplin,M. S., Preterm birth: a review of genetic factors and future directions for genetic study. Obstet. Gynecol. Surv. 2006, 61, 800-806.
14. Ilekis, J. V., Reddy, U. M., Roberts, J. M., Preeclampsia -a pressing problem: an executive summary of a national institute of child health and human development workshop. Reprod. Sci. 2007, 14, 508-523.
15. Roberts, J. M., Balk, J. L., Bodnar, L. M., Belizan, J.M. et al., Nutrient involvement in preeclampsia. J. Nutr. 2003, 133, 1684S-1692S.
16. Gilbert, J. S., Ryan, M. J., LaMarca, B. B., Sedeek, M. et al., Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H541-H550.
17. Brosens, I. A., Robertson,W. B., Dixon, H. G., The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet. Gynecol. Annu. 1972, 1, 177-191.
18. Zhou, Y., Damsky, C. H., Fisher, S. J. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J. Clin. Invest. 1997, 99, 2152-2164.
19. Roberts, J. M., Endothelial dysfunction in preeclampsia. Semin. Reprod. Endocrinol. 1998, 16, 5-15.
20. Hockel, M., Vaupel, P., Biological consequences of tumor hypoxia. Semin. Oncol. 2001, 28, 36-41.
21. Wheeler, T., Elcock, C. L., Anthony, F.W., Angiogenesis and the placental environment. Placenta 1995, 16, 289-296.
22. Gerber, H. P., Condorelli, F., Park, J., Ferrara, N., Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 1997, 272, 23659-23667.
23. Shweiki, D., Itin, A., Soffer, D., Keshet, E., Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-845.
24. Karumanchi, S. A., Bdolah, Y., Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. Endocrinology 2004, 145, 4835-4837.
25. Burton, G. J., Oxygen, the Janus gas; its effects on human placental development and function. J. Anat. 2009, 215, 27-35.
26. Roberts, C. T., IFPA award in placentology lecture: complicated interactions between genes and the environment in placentation, pregnancy outcome and long term health. Placenta 2010, 31, S47-S53.
27. Sargent, I. L., Germain, S. J., Sacks, G. P., Kumar, S. et al., Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J. Reprod. Immunol. 2003, 59, 153-160.
28. Mistry, H. D., Wilson, V., Ramsay, M. M., Symonds, M. E. et al., Reduced selenium concentrations and glutathione peroxidase activity in preeclamptic pregnancies. Hypertension 2008, 52, 881-888.
29. Redman, C. W., Sargent, I. L., Latest advances in understanding preeclampsia. Science 2005, 308, 1592-1594.
30. Sikkema, J. M., van Rijn, B. B., Franx, A., Bruinse, H. W. et al., Placental superoxide is increased in pre-eclampsia. Placenta 2001, 22, 304-308.
31. Walsh, S. W., Vaughan, J. E., Wang, Y., Roberts, L. J. 2nd, Placental isoprostane is significantly increased in preeclampsia. FASEB J. 2000, 14, 1289-1296.
32. Mehendale, S., Kilari, A., Dangat, K., Taralekar, V. et al., Fatty acids, antioxidants, and oxidative stress in preeclampsia. Int. J. Gynaecol. Obstet. 2008, 100, 234-238.
33. Sibai, B., Dekker, G., Kupferminc, M., Pre-eclampsia. Lancet 2005, 365, 785-799.
34. Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z., Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13, 9-22.
35. Yancopoulos, G. D., Klagsbrun, M., Folkman, J., Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 1998, 93, 661-664.
36. Maynard, S., Epstein, F. H., Karumanchi, S. A., Preeclampsia and angiogenic imbalance. Annu. Rev. Med. 2008, 59, 61-78.
37. Ahmad, S., Ahmed, A., Antiangiogenic effect of soluble vascular endothelial growth factor receptor-1 in placental angiogenesis. Endothelium 2005, 12, 89-95.
38. Schlembach, D.,Wallner,W., Sengenberger, R., Stiegler, E. et al., Angiogenic growth factor levels inmaternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet. Gynecol. 2007, 29, 407-413.
39. Kim, Y. M., Bujold, E., Chaiworapongsa, T., Gomez, R. et al., Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am. J. Obstet. Gynecol. 2003, 189, 1063-1069.
40. Rajakumar, A., Powers, R. W., Hubel, C. A., Shibata, E. et al., Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. Placenta 2009, 30, 25-34.
41. Muttukrishna, S., Suri, S., Groome, N., Jauniaux, E., Relationships between TGF beta proteins and oxygen concentrations inside the first trimester human gestational sac. PLoS One 2008, 3, e2302.
42. Kulkarni, A. V., Mehendale, S. S., Yadav, H. R., Joshi, S. R., Reduced placental docosahexaenoic acid levels associated with increased levels of sFlt-1 in preeclampsia. Prostaglandins Leukot. Essent. Fatty Acids 2011, 84, 51-55.
43. Laskowska, M., Laskowska, K., Leszczynska-Gorzelak, B., Oleszczuk, J., Are the maternal and umbilical VEGF-A and SVEGF-R1 altered in pregnancies complicated by preeclampsia with or without intrauterine foetal growth retardation? Preliminary communication. Med. Wieku Rozwoj. 2008, 12, 499-506.
44. Wikstrom, A. K., Larsson, A., Eriksson, U. J., Nash, P. et al., Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet. Gynecol. 2007, 109, 1368-1374.
45. Levine, R. J., Lam, C., Qian, C., Yu, K. F. et al., Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006, 355, 992-1005.
46. Shaarawy, M., Al-Sokkary, F., Sheba, M., Wahba, O. et al., Angiogenin and vascular endothelial growth factor in pregnancies complicated by preeclampsia. Int. J. Gynaecol. Obstet. 2005, 88, 112-117.
47. De Vivo, A., Baviera, G., Giordano, D., Todarello, G. et al., Endoglin, PlGF and sFlt-1 as markers for predicting preeclampsia. Acta. Obstet. Gynecol. Scand. 2008, 87, 837-842.
48. Kulkarni, A. V., Mehendale, S. S., Yadav, H. R., Kilari, A. S. et al., Circulating angiogenic factors and their association with birth outcomes in preeclampsia. Hypertens. Res. 2010, 33, 561-567.
49. Levine, R. J., Maynard, S. E., Qian, C., Lim, K. H. et al., Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004, 350, 672-683.
50. Robillard, P. Y., Hulsey, T. C., Alexander, G. R., Keenan, A. et al., Paternity patterns and risk of preeclampsia in the last pregnancy in multiparae. J. Reprod. Immunol. 1993, 24, 1-12.
51. Salha, O., Sharma, V., Dada, T., Nugent, D. et al., The influence of donated gametes on the incidence of hypertensive disorders of pregnancy. Hum. Reprod. 1999, 14, 2268-2273.
52. Keelan, J. A., Mitchell, M. D., Placental cytokines and preeclampsia. Front. Biosci. 2007, 12, 2706-2727.
53. Moffett, A., Hiby, S. E., How does the maternal immune system contribute to the development of pre-eclampsia? Placenta 2007, 28 Suppl A, S51-S56.
54. Kopcow, H. D., Karumanchi, S. A., Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia. J. Reprod. Immunol. 2007, 76, 23-29.
55. Hiby, S. E., Walker, J. J., O'Shaughnessy, K. M., Redman, C. W. et al., Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 2004, 200, 957-965.
56. Wang, C. C., Yim, K.W., Poon, T. C., Choy, K.W. et al., Innate immune response by ficolin binding in apoptotic placenta is associated with the clinical syndrome of preeclampsia. Clin. Chem. 2007, 53, 42-52.
57. Wang, Y., Gu, Y., Zhang, Y., Lewis, D. F. et al., Increased chymotrypsin-like protease (chymase) expression and activity in placentas from women with preeclampsia. Placenta 2007, 28, 263-269.
58. Quitterer, U., Lother, H., Abdalla, S., AT1 receptor heterodimers and angiotensin II responsiveness in preeclampsia. Semin. Nephrol. 2004, 24, 115-119.
59. Wallukat, G., Homuth, V., Fischer, T., Lindschau, C. et al., Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 1999, 103, 945-952.
60. Dechend, R., Viedt, C., Muller, D. N., Ugele, B. et al., AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 2003, 107, 1632-1639.
61. Irani, R. A., Xia, Y., The functional role of the reninangiotensin system in pregnancy and preeclampsia. Placenta 2008, 29, 763-771.
62. Zhou, C. C., Ahmad, S., Mi, T., Abbasi, S. et al., Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008, 51, 1010-1019.
63. Chappell, S., Morgan, L., Searching for genetic clues to the causes of pre-eclampsia. Clin. Sci. (Lond) 2006, 110, 443-458.
64. van Dijk, M., Oudejans, C. B., STOX1: key player in trophoblast dysfunction underlying early onset preeclampsia with growth retardation. J. Pregnancy 2011, 521826.
65. Berends, A. L., Bertoli-Avella, A. M., de Groot, C. J., van Duijn, C. M. et al., STOX1 gene in pre-eclampsia and intrauterine growth restriction. BJOG 2007, 114, 1163-1167.
66. Nafee, T. M., Farrell, W. E., Carroll, W. D., Fryer, A. A. et al., Epigenetic control of fetal gene expression. BJOG 2008, 115, 158-168.
67. Sood, R., Zehnder, J. L., Druzin, M. L., Brown, P. O., Gene expression patterns in human placenta. Proc. Natl. Acad. Sci. USA 2006, 103, 5478-5483.
68. Sitras, V., Paulssen, R. H., Gronaas, H., Leirvik, J. et al., Differential placental gene expression in severe preeclampsia. Placenta 2009, 30, 424-433.
69. Waterland, R. A., Is epigenetics an important link between early life events and adult disease? Horm. Res. 2009, 71 Suppl 1, 13-16.
70. Kulkarni, A., Mehendale, S., Pisal, H., Kilari, A. et al., Association of omega-3 fatty acids and homocysteine concentrations in preeclampsia. Clin. Nutr. 2011, 30, 60-64.
71. Kulkarni, A., Chavan-Gautam, P., Mehendale, S., Yadav, H. et al., Global DNA methylation patterns in placenta and its association with maternal hypertension in preeclampsia. DNA Cell Biol. 2011, 30, 79-84.
72. Chavan-Gautam, P., Sundrani, D., Pisal, H., Nimbargi, V. et al., Gestation-dependent changes in human placental global DNA methylation levels. Mol. Reprod. Dev. 2011, 78, 150.
73. Kolialexi, A., Mavrou, A., Tsangaris, G. T., Proteomic analysis of human reproductive fluids. Proteomics Clin. Appl. 2007, 1, 853-860.
74. Underwood, M. A., Gilbert, W. M., Sherman, M. P., Amniotic fluid: not just fetal urine anymore. J. Perinatol. 2005, 25, 341-348.
75. Cho, C. K., Shan, S. J., Winsor, E. J., Diamandis, E. P., Proteomics analysis of human amniotic fluid. Mol. Cell Proteomics 2007, 6, 1406-1415.
76. Song, H. J., Zhang, P., Guo, X. J., Liao, L. M. et al., The proteomic analysis of human neonatal umbilical cord serum by mass spectrometry. Acta. Pharmacol. Sin. 2009, 30, 1550-1558.
77. Chien, P. F., Arnott, N., Gordon, A., Owen, P. et al., How useful is uterine artery Doppler flow velocimetry in the prediction of preeclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 2000, 107, 196-208.
78. Podjarny, E., Losonczy, G., Baylis, C., Animal models of preeclampsia. Sem. Nephrol. 2004, 24, 596-606.
79. Abebe, J., Eigbefoh, J., Isabu, P., Okogbenin, S. et al., Accuracy of urine dipsticks, 2-h and 12-h urine collections for protein measurement as compared with the 24-h collection. J. Obstet. Gynaecol. 2008, 28, 496-500.
80. Shahbazian, N., Hosseini-Asl, F., A comparison of spot urine protein-creatinine ratio with 24-hour urine protein excretion in women with preeclampsia. Iran J. Kidney Dis. 2008, 2, 127-131.
81. Thangaratinam, S., Coomarasamy, A., O'Mahony, F., Sharp, S. et al., Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review. BMC Med. 2009, 7, 10.
82. Buhimschi, I. A., Zhao, G., Funai, E. F., Harris, N. et al., Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am. J. Obstet. Gynecol. 2008, 199, 551.e1-551.e16.
83. Silverman, G. A., Bird, P. I., Carrell, R. W., Church, F. C. et al., The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 2001, 276, 33293-33296.
84. Chelbi, S. T., Mondon, F., Jammes, H., Buffat, C. et al., Expressional and epigenetic alterations of placental serine protease inhibitors. Hypertension 2007, 49, 76-83.
85. Gupta, A., Gebhardt, S., Hillermann, R., Holzgreve,W. et al., Analysis of plasma elastase levels in early and late onset preeclampsia. Arch. Gynecol. Obstet. 2006, 273, 239-242.
86. Blumenstein, M.,McMaster, M. T., Black,M. A.,Wu, S. et al., A proteomic approach identifies early pregnancy biomarkers for preeclampsia: novel linkages between a predisposition to preeclampsia and cardiovascular disease. Proteomics 2009, 9, 2929-2945.
87. Vascotto, C., Salzano, A. M., D'Ambrosio, C., Fruscalzo, A. et al., Oxidized transthyretin in amniotic fluid as an early marker of preeclampsia. J. Proteome Res. 2006, 6, 160-170.
88. Auer, J., Camoin, L., Guillonneau, F., Rigourd, V., et al., Serum profile in preeclampsia and intra-uterine growth restriction revealed by iTRAQ technology. J. Proteomics 2010, 73, 1004-1017.
89. Chen, G., Zhang, Y., Jin, X., Zhang, L. et al., Urinary proteomics analysis for renal injury in hypertensive disorders of pregnancy with iTRAQ labeling and LC-MS/MS. Proteomics Clin. Appl. 2011, 5, 300-310.
90. Blumenstein, M., Prakash, R., Cooper, G. J., North, R. A., Aberrant processing of plasma vitronectin and high-molecular-weight kininogen precedes the onset of preeclampsia. Reprod. Sci. 2009, 16, 1144-1152.
91. Carty, D. M., Siwy, J., Brennand, J. E., Zurbig, P. et al., Urinary proteomics for prediction of preeclampsia. Hypertension, 2011, 57, 561-569.
92. Williams, V. K., Griffiths, A. B., Carbone, S., Hague, W. M., Fibrinogen concentration and factor VIII activity in women with preeclampsia. Hypertens. Pregnancy 2007, 26, 415-421.
93. Ka°rehed, K., Wikstrom, A. K., Olsson, A. K., Larsson, A. et al., Fibrinogen and histidine-rich glycoprotein in earlyonset preeclampsia. Acta. Obstet. Gynecol. Scand. 2010, 89, 131-139.
94. Dvergsten, J., Manivel, J. C., Correa-Rotter, R., Rosenberg, M. E., Expression of clusterin in human renal diseases. Kidney Int. 1994, 45, 828-835.
95. Shin, J. K., Han, K. A., Kang, M. Y., Kim, Y. S. et al., Expression of clusterin in normal and preeclamptic placentas. J. Obstet. Gynaecol Res. 2008, 34, 473-479.
96. Watanabe, H., Hamada, H., Yamada, N., Sohda, S. et al., Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia. Proteomics 2004, 4, 537-543.
97. Calero,M., Rostagno, A., Frangione, B., Ghiso, J., Clusterin and Alzheimer's disease. Subcell. Biochem. 2005, 38, 273-298.
98. Lim, J. H., Kim, S. Y., Park, S. Y., Yang, J. H. et al., Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet. Gynecol. 2008, 111, 1403-1409.
99. Robinson, C. J., Johnson, D. D., Soluble endoglin as a second-trimester marker for preeclampsia. Am. J. Obstet. Gynecol. 2007, 197, 174.e1-174.e5.
100. Moore Simas, T. A., Crawford, S. L., Solitro, M. J., Frost, S. C. et al., Angiogenic factors for the prediction of preeclampsia in high-risk women. Am. J. Obstet. Gynecol. 2007, 197, 244.e1-244.e8.
101. Maynard, S. E., Min, J. Y., Merchan, J., Lim, K. H. et al., Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003, 111, 649-658.
102. Venkatesha, S., Toporsian, M., Lam, C., Hanai, J. et al., Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 2006, 12, 642-649.
103. Bolin, M., Akerud, P., Hansson, A., Akerud, H., Histidinerich glycoprotein as an early biomarker of preeclampsia. Am. J. Hypertens. 2011, 24, 496-501.
104. Rasanen, J., Girsen, A., Lu, X., Lapidus, J. A. et al., Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J. Proteome Res. 2010, 9, 4274-4281.
105. Blankley, R. T., Gaskell, S. J., Whetton, A. D., Dive, C. et al., A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of preeclampsia. BJOG 2009, 116, 1473-1480.
106. Zhang, H., Zhang, Y., Yang, F., Li, L. et al., Complement component C4A and apolipoprotein A-I in plasmas as biomarkers of the severe, early-onset preeclampsia. Mol. Biosyst. 2011, 7, 2470-2479.
107. Park, J., Cha, D. H., Lee, S. J., Kim, Y. N. et al., Discovery of the serum biomarker proteins in severe preeclampsia by proteomic analysis. Exp. Mol. Med. 2011, 43, 427-435.
108. Norwitz, E. R., Tsen, L. C., Park, J. S., Fitzpatrick, P. A. et al., Discriminatory proteomic biomarker analysis identifies free hemoglobin in the cerebrospinal fluid of women with severe preeclampsia. Am. J. Obstet. Gynecol. 2005, 193, 957-964.
109. Foyouzi, N., Norwitz, E. R., Tsen, L. C., Buhimschi, C. S. et al., Placental growth factor in the cerebrospinal fluid of women with preeclampsia. Int. J. Gynecol. Obstet. 2006, 92, 32-37.
110. Celik, O., Hascalik, S., Ozerol, E., Hascalik, M. et al., Cerebrospinal fluid leptin levels in preeclampsia: relation to maternal serum leptin levels. Acta Obstet. Gynecol. Scand. 2004, 83, 519-523.
111. Myers, J., Macleod, M., Reed, B., Harris, N. et al., Use of proteomic patterns as a novel screening tool in preeclampsia. J. Obstet. Gynaecol. 2004, 24, 873-874.
112. Liu, C., Zhang, N., Yu, H., Chen, Y. et al., Proteomic analysis of human serum for finding pathogenic factors and potential biomarkers in preeclampsia. Placenta 2011, 32, 168-174.
113. Buhimschi, I. A., Buhimschi, C. S., Proteomics of the amniotic fluid in assessment of the placenta. Relevance for preterm birth. Placenta 2008, 29 Suppl A, 95-101.
114. Romero, R., Espinoza, J., Rogers,W. T., Moser, A. et al., Proteomic analysis of amniotic fluid to identify women with preterm labor and intra-amniotic inflammation/infection: The use of a novel computational method to analyze mass spectrometric profiling. J. Matern. Fetal Neonatal Med. 2008, 21, 367-388.
115. Park, J. S., Oh, K. J., Norwitz, E. R., Han, J. S. et al., Identification of proteomic biomarkers of preeclampsia in amniotic fluid using SELDI-TOF mass spectrometry. Reprod. Sci. 2008, 15, 457-468.
116. Page, E. W. The relation between hydatid moles, relative ischaemia of the gravid uterus and the placental origin of eclampsia. Am. J. Obstet. Gynecol. 1939, 37, 291-293.
117. Kim, Y. N., Kim, H. K., Warda, M., Kim, N. et al., Toward a better understanding of preeclampsia: comparative proteomic analysis of preeclamptic placentas. Proteomics Clin. Appl. 2007, 1, 1625-1636.
118. Gharesi-Fard, B., Zolghadri, J., Kamali-Sarvestani, E., Proteome differences of placenta between preeclampsia and normal pregnancy. Placenta 2010, 31, 121-125.
119. Centlow, M., Hansson, S. R., Welinder, C., Differential proteome analysis of the preeclamptic placenta using optimized protein extraction. J. Biomed. Biotechnol. 2010, 2010, 458748.
120. Mine, K., Katayama, A., Matsumura, T., Nishino, T. et al., Proteome analysis of human placentae: pre-eclampsia versus normal pregnancy. Placenta 2007, 28, 676-687.
121. Blankley, R. T., Robinson, N. J., Aplin, J. D., Crocker, I. P. et al., A gel-free quantitative proteomics analysis of factors released from hypoxic-conditioned placentae. Reprod. Sci. 2010, 17, 247-257.
122. Johnstone, E. D., Sawicki, G., Guilbert, L., Winkler-Lowen, B. et al., Differential proteomic analysis of highly purified placental cytotrophoblasts in pre-eclampsia demonstrates a state of increased oxidative stress and reduced cytotrophoblast antioxidant defense. Proteomics 2011, 20, 4077-4084.
123. Sun, L. Z., Yang, N. N., De, W., Xiao, Y. S., Proteomic analysis of proteins differentially expressed in preeclamptic trophoblasts. Gynecol. Obstet. Invest. 2007, 64, 17-23.
124. Jin, H., Ma, K. D., Hu, R., Chen, Y. et al., Analysis of expression and comparative profile of normal placental tissue proteins and those in preeclampsia patients using proteomic approaches. Anal. Chim. Acta 2008, 629, 158-164.
125. Hoang, V. M., Foulk, R., Clauser, K., Burlingame, A. et al., Functional proteomics: examining the effects of hypoxia on the cytotrophoblast protein repertoire. Biochemistry 2001, 40, 4077-4086.
126. Hu, R., Jin, H., Zhou, S., Yang, P. et al., Proteomic analysis of hypoxia-induced responses in the syncytialization of human placental cell line BeWo. Placenta 2007, 28, 399-407.
127. Sawicki, G., Dakour, J., Morrish, D. W., Functional proteomics of neurokinin B in the placenta indicates a novel role in regulating cytotrophoblast antioxidant defences. Proteomics 2003, 3, 2044-2051.
128. Ishioka, S., Ezaka, Y., Umemura, K., Hayashi, T. et al., Proteomic analysis of mechanisms of hypoxia-induced apoptosis in trophoblastic cells. Int. J. Med. Sci. 2006, 4, 36-44.
129. Walther, T., Wallukat, G., Jank, A., Bartel, S. et al., Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 2005, 46, 1275-1279.
130. Xia, Y., Kellems, R. E., Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev. Clin. Immunol. 2011, 7, 659-674.
131. Rauch, J., Gires, O., SEREX, Proteomex, AMIDA, and beyond: serological screening technologies for target identification. Proteomics Clin. Appl. 2008, 2, 355-371.
132. Tjalsma, H., Schaeps, R. M., Swinkels, D. W., Immunoproteomics: from biomarker discovery to diagnostic applications. Proteomics Clin. Appl. 2008, 2, 167-180.
133. Cooke, C. L., Brockelsby, J. C., Baker, P. N., Davidge, S. T., The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia. Hypertens. Pregnancy 2003, 22, 173-184.
134. Chekir, C., Nakatsuka, M., Noguchi, S., Konishi, H. et al., Accumulation of advanced glycation end products in women with preeclampsia: possible involvement of placental oxidative and nitrative stress. Placenta 2006, 27, 225-233.
135. Kwon, J. H., Kim, Y. H., Kwon, J. Y., Park, Y. W., Clinical significance of serum sRAGE and esRAGE in women with normal pregnancy and preeclampsia. J. Perinat. Med. 2011, 39, 507-513.
136. Webster, R. P.,Myatt, L., Elucidation of themolecular mechanisms of preeclampsia using proteomic technologies. Proteomics Clin. Appl. 2007, 1, 1147-1155.
137. Zhang, H. H., Wang, Y. P., Chen, D. B., Analysis of nitrosoproteomes in normotensive and severe preeclamptic human placentas. Biol. Reprod. 2011, 84, 966-975.
138. Atkinson, K. R., Blumenstein, M., Black, M. A., Wu, S. H. et al., An altered pattern of circulating apolipoprotein E3 isoforms is implicated in preeclampsia. J. Lipid Res. 2009, 50, 71-80.
139. Shin, J. K., Baek, J. C., Kang, M. Y., Park, J. K. et al., Proteomic analysis reveals an elevated expression of heat shock protein 27 in preeclamptic placentas. Gynecol. Obstet. Invest. 2011, 71, 151-157.
140. Ahmad, S., Hewett, P. W., Al-Ani, B., Sissaoui, S. et al., Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. Vasc. Cell 2011, 3, 15.
141. Scioscia, M., Gumaa, K., Kunjara, S., Paine, M. A. et al., Insulin resistance in human preeclamptic placenta is mediated by serine phosphorylation of insulin receptor substrate-1 and -2. J. Clin. Endocrinol. Metab. 2006, 91, 709-717.